Renovacor Announces the Appointment of Jordan Shin, M.D., Ph.D., as Senior Vice President of Clinical Development and Translational Science
Sep 22, 2021Dr. Shin to help advance REN-001 into the clinic by leveraging nearly two decades of expertise in clinical development, academic research and medical practice
PHILADELPHIA–(BUSINESS WIRE)– Renovacor, Inc. (NYSE: RCOR), an early-stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Jordan Shin, M.D., Ph.D., as Senior Vice President of Clinical Development and Translational Science.